SAN DIEGO--(BUSINESS WIRE)--Sequenom, Inc. (NASDAQ: SQNM) today announced that its non-invasive fetal Rhesus D (RHD) genotyping assay demonstrated 100% concordance with routine European non-invasive Real-time PCR (RT-PCR) methods. This data demonstrates that the research use only fetal RHD genotyping assay utilizing Sequenom’s MassARRAY® technology may be a suitable alternative for clinical assessment of prenatal RHD incompatibility.
